Abstract:ID 93958 Poster Board 481 A 3 adenosine receptor (AR) agonists are being developed for the treatment of autoimmune inflammatory diseases, chronic pain and cancer. A 3 AR agonists are not limited by cardiovascular side effects observed with other adenosine (A 1 and A 2A ) agonists that were in clinical trials. 2-Arylethynyl (North)-methanocarba adenosines have been explored as highly selective A 3 AR agonists, which is largely a function of the pseudoribose (bicyclic fused cyclopropane and cyclopentane) ring that pre-establishes a preferred (N) conformation for receptor recognition. Here, we compare analogues in the 5¢methylamide series having bulky C2-substitution, which either contain or lack an ethynyl spacer between adenine and a cyclic group. 2-Aryl compounds 11 , 13 , 14 , 19 , 22 , 23 , 27 , 29 , 31 and 34 , lacking an ethynyl spacer, displayed potent K i values of 2–30 nM at the human (h) A 3 AR, while other derivatives had greatly reduced affinity. The mouse (m) A 3 AR affinity was highly variable, with 2-arylethynyl groups greatly favoring high affinity ( 7 , 8 > 3c , 3d > 3b ) compared to 2-aryl analogues. However, 4¢truncated derivatives lacking a 2-ethynyl spacer had greatly reduced hA 3 AR affinity, even for those analogues containing affinity-enhancing N 6 -dopamine-derived substituents. This suggests that the 5¢methylamide group is especially important for anchoring these analogues in a deep hydrophilic subpocket in the receptor. hA 3 AR homology modeling indicated that 2-aryl and 2-arylethynyl groups have different conformations and receptor environments. The directly connected 2-aryl groups interact with ECL2 of the hA 3 AR, as opposed to the 2-arylethynyl groups, which interact with TM2. Functional assays of selected compounds in G protein-dependent and independent signaling were performed using engineered HEK293T cell lines. In a hA 3 AR miniG α i recruitment assay, 31 (MRS8062) was (slightly) more potent compared to a β-arrestin2 recruitment assay, and its maximal efficacy (E max ) was much higher (165%) than reference nonselective agonist NECA. Thus, in the 2-aryl series, A 3 AR affinity and selectivity were variable and generally reduced compared to the 2-arylethynyl series, with a greater dependence on the specific aryl group present. Selected compounds were protective in an vivo ischemic model of peripheral artery disease (PAD), in which other A 3 AR agonists demonstrated efficacy. Compounds 3a – 3c in the rigidified 2-arylethynyl series significantly decreased the % cell death in this model of skeletal muscle ischemia reperfusion injury/claudication, as previously shown only for moderately A 3 AR-selective ribosides or (N)-methanocarba derivatives (all lacking the 2-arylethynyl group). Thus, we have expanded A 3 AR agonist SAR for (N)-methanocarba adenosines and their application to skeletal muscle ischemia. NIDDK Intramural Res. ZIADK031117

Structure-Activity Studies of 1 H -Imidazo[4,5- c ]quinolin-4-amine Derivatives as A 3 Adenosine Receptor Positive Allosteric Modulators

Extrahelical Binding Site for a 1H-Imidazoquinolin-4-amine A3 Adenosine Receptor Positive Allosteric Modulator on Helix 8 and Distal Portions of Transmembrane Domains 1 and 7

The design, synthesis and α7 nicotinic acetylcholine receptors positive allosteric modulative evaluation of 3H-quinazolin-4-one derivatives

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

Species differences and mechanism of action of A3 adenosine receptor allosteric modulators

Novel Fused Arylpyrimidinone Based Allosteric Modulators of the M1 Muscarinic Acetylcholine Receptor

Novel Quinazoline Derivatives as Highly Effective A2A Adenosine Receptor Antagonists

2-Substituted -Methanocarba A3 Adenosine Receptor Agonists: In silico, in vitro and in vivo Characterization

Hit-to-Lead Optimization of Heterocyclic Carbonyloxycarboximidamides as Selective Antagonists at Human Adenosine A3 Receptor

2-Aryladenine Derivatives as a Potent Scaffold for Adenosine Receptor Antagonists: The 6-Morpholino Derivatives

A3 adenosine receptor agonists containing dopamine moieties for enhanced interspecies affinity

Medicinal chemistry of adenosine A3 receptor ligands

( S )- N -Benzyl-1-phenyl-3,4-dihydroisoqunoline-2(1 H )-carboxamide Derivatives, Multi-Target Inhibitors of Monoamine Oxidase and Cholinesterase: Design, Synthesis, and Biological Activity.

QSAR Analysis of Human Adenosine A3 Receptor Antagonists

Structure activity relationship studies of natural product chemokine receptor CCR5 antagonist anibamine toward the development of novel anti prostate cancer agents.

Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist

Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.

Discovery of 2-Methyl-5-(1 H -pyrazol-4-yl)pyridines and Related Heterocycles as Promising M 4 mAChR Positive Allosteric Modulators for the Treatment of Neurocognitive Disorders

Design, synthesis and evaluation of novel 2-phenyl-3-(1 H -pyrazol-4-yl)pyridine positive allosteric modulators for the M 4 mAChR

Discovery of Novel Benzo[4,5]imidazo[1,2- a ]pyrazin-1-amine-3-amide-one Derivatives as Anticancer Human A 2A Adenosine Receptor Antagonists

Novel selective antagonist radioligands for the pharmacological study of A2B adenosine receptors